UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
NHLBI-MDS
|
The National Myelodysplatic Syndromes (MDS) Study |
Open |
ACCL1633
|
The Effectiveness of Lactobacillus plantarum (LBP, IND# 17339) in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) |
Open |
APEC14B1
|
Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study |
Open |
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
AALL1131
|
Phase 3 Randomized Trial for Newly Diagnosed High Risk B- Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
|
Open |
AGCT1532
|
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
Open |
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
ALTE07C1
|
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer |
Open |
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
APEC1621J
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations |
Open |
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
APEC1621C
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tazemetostat in Patients with tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex |
Not Open |
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
UW14108
|
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (CCTL019A2205B) |
Open |
AALL1631
|
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones |
Open |
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
UW15106
|
Genomic Analysis of Long-Term Survivors with Metastatic Cancer |
Open |
UW16144
|
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
|
Open |
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
S1612
|
A Randomized Phase II/III Trial of "Novel Therapeutics: Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older |
Open (affiliates only) |
AAML1331
|
A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid |
Open |
E1910
|
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL Negative B Lineage Acute Lymphoblastic Leukemia in Adults |
Open |
UW13043
|
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014 |
Open |
UW16061
|
A Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL) |
Open |
NCI9782
|
A Phase 1 Study of Talazoparib (BMN 673) in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors |
Open |
UW17114
|
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
|
Open |
BMTCTN1506
|
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy following Allogeneic Transplant for Patients with FLT3/ITD AML |
Open |